Nhwa Pharma Acquires China Rights to Emergency Treatment for Blood Loss

Jiangsu Nhwa Pharma, a Xuzhou pharma with CNS and cardiovascular offerings, in-licensed China rights to a clinical stage oxygen treatment from NuvOx Pharma of Tuscon, Arizona. NVX-408 is designed as an emergency treatment to improve survival in people suffering from severe blood loss, either from accident or surgery. According to the company, NVX-408 does not cause allergic reactions. The financial terms of the agreement were not disclosed. More details.... Share this with colleagues: // //